BOSTON -- Thanks for returning to the Biotech Mailbag. I do my best to respond to your comments and questions, so please email me here.

This week's Mailbag:

Biogen Idec ( BIIB) and Elan ( ELN)

Synta Pharmaceuticals ( SNTA)

Repros Therapeutics ( RPRX) and Indevus Pharmaceuticals ( IDEV)

PDL BioPharma ( PDLI)


Everyone loves a chuckle, especially on a Saturday, so let's kick off with a very funny letter from a guy who identifies himself as "G F Urself." Apparently, Mr. Urself is a bit peeved at something I said in last week's Mailbag about Biogen Idec. (I wonder what G F stands for?)

I wrote : "And what happens if another fatal or disabling case of progressive multifocal leukoencephalopathy (PML) crops up in a Tysabri patient? I guess I'm on the fence about Biogen Idec."

To which, Mr. Urself emailed to me:

"How about you 'guess' you are and have been a disingenuous hatchet shill, bought and paid for by a competitor that produces a drug that tries to compete in the mktplace sic with Tysabri? I'll continue to enjoy watching the user numbers and their inexorable climb upward at the expense of your handler's offerings; it is inevitable ... Shalom Ahole sic. "

Apparently, someone forget to take their meds ...

I don't know if Urself is an investor in Biogen Idec or Tysabri marketing partner Elan (I'm guessing the latter) but if he does own Biogen Idec, he's one happy (albeit still twisted) camper this morning after the big news that broke Friday night.

If you liked this article you might like

Goodbye

Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio